Last reviewed · How we verify
MMRvaxpro
MMRvaxpro is a live attenuated vaccine that stimulates the immune system to produce antibodies and cellular immunity against measles, mumps, and rubella viruses.
MMRvaxpro is a live attenuated vaccine that stimulates immune response against measles, mumps, and rubella viruses. Used for Prevention of measles, mumps, and rubella in children and adults.
At a glance
| Generic name | MMRvaxpro |
|---|---|
| Sponsor | Rigshospitalet, Denmark |
| Drug class | Live attenuated vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains weakened (attenuated) strains of measles, mumps, and rubella viruses that replicate in the body without causing disease. This triggers both humoral (antibody-mediated) and cell-mediated immune responses, providing long-term protection against these three viral infections. The attenuated viruses are unable to cause the severe manifestations of wild-type infection while still generating robust immunological memory.
Approved indications
- Prevention of measles, mumps, and rubella in children and adults
Common side effects
- Fever
- Rash
- Local injection site reactions (pain, redness, swelling)
- Parotitis (mumps-like symptoms)
- Arthralgia/arthritis
Key clinical trials
- MMR at 6 Months Trial (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MMRvaxpro CI brief — competitive landscape report
- MMRvaxpro updates RSS · CI watch RSS
- Rigshospitalet, Denmark portfolio CI